Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Eisai Acquires Four Oncology- Related Products From Ligand

December 1, 2006
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 12
Volume 15
Issue 12

Eisai Inc., the US subsidiary of Tokyo-based Eisai Co. Ltd., has completed acquisition of four oncology-related products from Ligand Pharmaceuticals: Ontak (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1%, and Panretin (alitretinoin gel 0.1%. In other news, the company said it has begun work on a new oncology facility in Research Triangle Park, North Carolina.

TEANECK, New Jersey—Eisai Inc., the US subsidiary of Tokyo-based Eisai Co. Ltd., has completed acquisition of four oncology-related products from Ligand Pharmaceuticals: Ontak (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1%, and Panretin (alitretinoin gel 0.1%. In other news, the company said it has begun work on a new oncology facility in Research Triangle Park, North Carolina.

Articles in this issue

Best Rx Most Cost-Effective: RTOG
Grape Seed Found to Be a Natural Aromatase Inhibitor
Drug Combination Prevents ER-Negative Tumors in Mice
Democrats' Agenda May Stifle Efforts for More Ca Funding
No Loss of Efficacy With Synchronous Chemotherapy/ESP
'Share Care' Difficult for Ca Survivors and Their Oncologists
Biomarkers Panel Promising for Detecting Pancreatic Ca
Preop Avastin/Tarceva in RCC
Aggressive Hyperglycemia Control Essential in Patients With Diabetes Hospitalized for Treatment of Cancer
Reovirus Agent Shows Activity in Phase I Trial
Eisai Acquires Four Oncology- Related Products From Ligand
Genetic Brain Tumor Study Gets $11 Million NCI Grant
Postoperative RT Boosts Survival in N2 Lung Ca Patients
ACCC Weighs in on Critical Cancer Care Issues:
Treatment Strategies Needed for Subpopulations of Colorectal Cancer Patients
Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Related Content
Advertisement

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Roman Fabbricatore
September 27th 2025
Article

Artificial intelligence can be used to automate genetic counseling processes and streamline a patient’s communication with relatives regarding genetic risk.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.

Indirect Comparison Favors Zanubrutinib vs Venetoclax Combo in CLL/SLL

Russ Conroy
September 26th 2025
Article

An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Following over a decade of oversight, no cases of Torsades de pointes or unexplained sudden deaths were reported among US patients who received vandetanib in REMS assessments.

FDA Drops REMS Requirement for Vandetanib in Medullary Thyroid Cancer

Tim Cortese
September 26th 2025
Article

Physicians are no longer required to have special certification to administer vandetanib to patients with medullary thyroid cancer.


Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

ONCOLOGY Staff
September 26th 2025
Article

Experts at City of Hope explore innovative immunotherapy strategies for non-small cell lung cancer, highlighting efficacy and toxicity management in treatment.

Related Content
Advertisement

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Underscoring Genetic Testing’s Role in Enhancing Ovarian Cancer Care

Roman Fabbricatore
September 27th 2025
Article

Artificial intelligence can be used to automate genetic counseling processes and streamline a patient’s communication with relatives regarding genetic risk.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.

Indirect Comparison Favors Zanubrutinib vs Venetoclax Combo in CLL/SLL

Russ Conroy
September 26th 2025
Article

An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Following over a decade of oversight, no cases of Torsades de pointes or unexplained sudden deaths were reported among US patients who received vandetanib in REMS assessments.

FDA Drops REMS Requirement for Vandetanib in Medullary Thyroid Cancer

Tim Cortese
September 26th 2025
Article

Physicians are no longer required to have special certification to administer vandetanib to patients with medullary thyroid cancer.


Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

Multidisciplinary Team Discusses Practical Treatment Options in NSCLC

ONCOLOGY Staff
September 26th 2025
Article

Experts at City of Hope explore innovative immunotherapy strategies for non-small cell lung cancer, highlighting efficacy and toxicity management in treatment.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.